|
May 19
|
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
|
|
May 15
|
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ...
|
|
May 15
|
Q1 2025 DiaMedica Therapeutics Inc Earnings Call
|
|
May 14
|
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
|
|
May 13
|
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
|
|
Mar 11
|
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
|
|
Feb 24
|
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
|
|
Feb 20
|
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
|
|
Feb 10
|
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
|
|
Jun 26
|
DiaMedica Therapeutics Announces $11.8 Million Private Placement
|
|
Jun 26
|
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
|
|
May 28
|
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
|
|
May 13
|
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript
|
|
May 8
|
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
|
|
May 2
|
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
|
|
May 1
|
Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
|
|
Apr 18
|
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
|
|
Apr 17
|
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
|
|
Apr 15
|
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Mar 25
|
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript
|